← Leaderboards
Michael Jackson
University Of California Santa Barbara
$21,435,916
Attributed
$36,363,353
Total exposure
18
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.2M · FY2012–25$10M$7.5M$5M$2.5M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,863,353 · 19
By mechanism
R01$20,315,749 · 8
U54$8,544,695 · 2
UH3$6,363,247 · 1
UG3$3,588,880 · 1
R56$1,800,549 · 1
P30$1,328,983 · 3
Top collaborators
- Seth J Field5 shared
- Kenneth S Kosik4 shared
- Lawrence S. Barak3 shared
- Anthony Bruce Pinkerton3 shared
- Bradley T Hyman2 shared
- Paul J Kenny2 shared
- Edwin S Monuki2 shared
- Layton Harris Smith2 shared
Others in their field
Top investigators on “High Throughput Screening”
- Richard A Gibbs · Baylor College Of Medicine$250,166,309
- Leonard Freedman · Leidos Biomedical Research, Inc.$249,633,249
- David Heimbrook · Leidos Biomedical Research, Inc.$181,270,700
- Peter B. Gilbert · Fred Hutchinson Cancer Center$146,111,713
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
Research focus
High Throughput ScreeningCellsAlzheimer&AposSmall MoleculeIn VitroScreeningLeadPharmaceutical ChemistryPhenotypePropertyLibrariesIn VivoAnalogEffective TherapySeriesSignal TransductionPublishingScaffoldPharmaceutical PreparationsProteinsValidationBrainAffectBinding
Grant awards (45)
Discovery and optimization of ApoE4 correctors for the treatment of Alzheimer's Disease$877,636
R01 · FY2025 · AG · contact PI
Preventing Tau uptake by novel inhibitors of tau binding to LRP1$786,735
R01 · FY2025 · AG
Brain-penetrant GPR88 agonists as novel therapeutics for opioid abuse$644,048
R01 · FY2025 · DA · contact PI
Targeting the mutant promoter of Telomerase Reverse Transcriptase (TERT)$631,711
R01 · FY2025 · CA
Cancer Molecular Therapeutics$255,113
P30 · FY2025 · CA · contact PI
Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders$1,348,795
UH3 · FY2024 · DA · contact PI
Discovery and development of apoE4 correctors for the treatment of Alzheimer's disease$881,443
R56 · FY2024 · AG · contact PI
Preventing Tau uptake by novel inhibitors of tau binding to LRP1$809,235
R01 · FY2024 · AG
A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs$785,074
R01 · FY2024 · MH · contact PI
Discovery and optimization of ApoE4 correctors for the treatment of Alzheimer's Disease$730,480
R01 · FY2024 · AG · contact PI
Targeting the mutant promoter of Telomerase Reverse Transcriptase (TERT)$563,904
R01 · FY2024 · CA
Mechanism of Action of a Novel Golgi-Targeted Anti-Cancer Agent$519,807
R01 · FY2024 · CA
Chemical Library Screening$195,512
P30 · FY2024 · CA · contact PI
Cancer Molecular Therapeutics$80,566
P30 · FY2024 · CA · contact PI
Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders$5,014,452
UH3 · FY2023 · DA · contact PI
Discovery and development of apoE4 correctors for the treatment of Alzheimer's disease$919,106
R56 · FY2023 · AG · contact PI
A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs$871,671
R01 · FY2023 · MH · contact PI
Preventing Tau uptake by novel inhibitors of tau binding to LRP1$853,145
R01 · FY2023 · AG
Targeting the mutant promoter of Telomerase Reverse Transcriptase (TERT)$772,180
R01 · FY2023 · CA
Mechanism of Action of a Novel Golgi-Targeted Anti-Cancer Agent$608,794
R01 · FY2023 · CA
Chemical Library Screening$199,448
P30 · FY2023 · CA · contact PI
Brain-penetrant GPR88 agonists as novel therapeutics for opioid abuse$2,150,978
R01 · FY2022 · DA · contact PI
A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs$907,259
R01 · FY2022 · MH · contact PI
Preventing Tau uptake by novel inhibitors of tau binding to LRP1$885,722
R01 · FY2022 · AG
Mechanism of Action of a Novel Golgi-Targeted Anti-Cancer Agent$655,747
R01 · FY2022 · CA
Optimization and Characterization of "MYC Degraders" for Pediatric Medulloblastoma$487,500
R33 · FY2022 · NS · contact PI
Chemical Library Screening$199,448
P30 · FY2022 · CA · contact PI
A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs$876,038
R01 · FY2021 · MH
Mechanism of Action of a Novel Golgi-Targeted Anti-Cancer Agent$733,096
R01 · FY2021 · CA
Chemical Library Screening$199,448
P30 · FY2021 · CA · contact PI
Optimization and Characterization of "MYC Degraders" for Pediatric Medulloblastoma$975,000
R61 · FY2020 · NS · contact PI
A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs$936,860
R01 · FY2020 · MH
Mechanism of Action of a Novel Golgi-Targeted Anti-Cancer Agent$739,493
R01 · FY2020 · CA
High Throughput Screen to Discover Modulators of TREM2 Activity$415,290
R01 · FY2020 · AG · contact PI
Chemical Library Screening$199,448
P30 · FY2020 · CA · contact PI
Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders$3,588,880
UG3 · FY2019 · DA · contact PI
High Throughput Screen to Discover Modulators of TREM2 Activity$415,290
R01 · FY2019 · AG · contact PI
Optimization of glucocorticoid receptor (GR) passive antagonists for the treatment of post-traumatic stress disorder (PTSD)$459,360
R01 · FY2018 · MH
High Throughput Screen to Discover Modulators of TREM2 Activity$439,040
R01 · FY2018 · AG · contact PI
Optimization of glucocorticoid receptor (GR) passive antagonists for the treatment of post-traumatic stress disorder (PTSD)$635,352
R01 · FY2017 · MH
Developing Choroid Plexus-Based Tools and Drug Screens$241,875
R21 · FY2017 · MH
Optimization of glucocorticoid receptor (GR) passive antagonists for the treatment of post-traumatic stress disorder (PTSD)$611,804
R01 · FY2016 · MH
Developing Choroid Plexus-Based Tools and Drug Screens$216,875
R21 · FY2016 · MH
Sanford-Burnham Center for Chemical Genomics$7,500,000
U54 · FY2012 · HG · contact PI
Administrative Core$1,044,695
U54 · FY2012 · HG · contact PI